For patients with myelodysplastic syndrome (MDS), a condition that affects the production of blood cells in the bone marrow, the clinical course is highly variable. While those with very low-risk MDS have a median survival of nearly a decade, patients with very high-risk MDS have a median survival of less than one year.
During the National Comprehensive Cancer Network (NCCN) 2022 Annual Congress: Hematologic Malignancies, Uma M. Borate, MD, MSc, an associate clinical professor of